Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer.
AuthorsPerry, Antoinette S
Raheem, Omer A
Murphy, Therese M
Hewitt, Stephen M
AffiliationProstate Molecular Oncology, Department of Clinical Medicine, Institute of Molecular Medicine, Trinity College Dublin, Ireland. email@example.com
Gene Expression Profiling
Cell Line, Tumor
Gene Expression Profiling
Promoter Regions, Genetic
Real-Time Polymerase Chain Reaction
Reverse Transcriptase Polymerase Chain Reaction
MetadataShow full item record
CitationPerry AS et al. Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. Int. J. Cancer 2013, 132 (8):1771-80
JournalInternational journal of cancer. Journal international du cancer
AbstractAberrant activation of Wnts is common in human cancers, including prostate. Hypermethylation associated transcriptional silencing of Wnt antagonist genes SFRPs (Secreted Frizzled-Related Proteins) is a frequent oncogenic event. The significance of this is not known in prostate cancer. The objectives of our study were to (i) profile Wnt signaling related gene expression and (ii) investigate methylation of Wnt antagonist genes in prostate cancer. Using TaqMan Low Density Arrays, we identified 15 Wnt signaling related genes with significantly altered expression in prostate cancer; the majority of which were upregulated in tumors. Notably, histologically benign tissue from men with prostate cancer appeared more similar to tumor (r = 0.76) than to benign prostatic hyperplasia (BPH; r = 0.57, p < 0.001). Overall, the expression profile was highly similar between tumors of high (≥ 7) and low (≤ 6) Gleason scores. Pharmacological demethylation of PC-3 cells with 5-Aza-CdR reactivated 39 genes (≥ 2-fold); 40% of which inhibit Wnt signaling. Methylation frequencies in prostate cancer were 10% (2/20) (SFRP1), 64.86% (48/74) (SFRP2), 0% (0/20) (SFRP4) and 60% (12/20) (SFRP5). SFRP2 methylation was detected at significantly lower frequencies in high-grade prostatic intraepithelial neoplasia (HGPIN; 30%, (6/20), p = 0.0096), tumor adjacent benign areas (8.82%, (7/69), p < 0.0001) and BPH (11.43% (4/35), p < 0.0001). The quantitative level of SFRP2 methylation (normalized index of methylation) was also significantly higher in tumors (116) than in the other samples (HGPIN = 7.45, HB = 0.47, and BPH = 0.12). We show that SFRP2 hypermethylation is a common event in prostate cancer. SFRP2 methylation in combination with other epigenetic markers may be a useful biomarker of prostate cancer.
- SFRP1 repression in prostate cancer is triggered by two different epigenetic mechanisms.
- Authors: García-Tobilla P, Solórzano SR, Salido-Guadarrama I, González-Covarrubias V, Morales-Montor G, Díaz-Otañez CE, Rodríguez-Dorantes M
- Issue date: 2016 Nov 30
- Promoter methylation of SFRPs gene family in cervical cancer.
- Authors: Chung MT, Sytwu HK, Yan MD, Shih YL, Chang CC, Yu MH, Chu TY, Lai HC, Lin YW
- Issue date: 2009 Feb
- Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
- Authors: Veeck J, Noetzel E, Bektas N, Jost E, Hartmann A, Knüchel R, Dahl E
- Issue date: 2008 Nov 6
- Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
- Authors: Henrique R, Jerónimo C, Hoque MO, Carvalho AL, Oliveira J, Teixeira MR, Lopes C, Sidransky D
- Issue date: 2005 Apr
- Epigenetic inactivation of secreted frizzled-related protein 2 in esophageal squamous cell carcinoma.
- Authors: Hao XW, Zhu ST, He YL, Li P, Wang YJ, Zhang ST
- Issue date: 2012 Feb 14